Seeking male and female participants who are under 22 years of age at enrollment with newly diagnosed de novo AML (a cancer of the bone marrow) for participation in a study comparing standard chemotherapy to one or more investigational drugs.
We are studying a combination of one or more investigational drugs in addition to chemotherapy for patients newly diagnosed with AML. Treatment for AML involves high doses of a common class of chemotherapy drugs, but can have long term side-effects. We are interested in finding an effective treatment for AML that reduces the potential long term side effects.
What we're hoping for
To evaluate the safety and efficacy of the drugs CPX-351 with daunorubicin and cytarabine and gilteritinib on people with newly diagnosed AML, to determine which is better.
ClinicalTrials.gov Identifier: NCT04293562